OBJECTIVE: To evaluate the long-term potency after radical prostatectomy (RP) with the early use of a vacuum erection device (VED), and reasons for sexual inactivity and long-term attrition and maintenance of sexual activity, as RP is one of the most common treatments for prostate cancer but erectile dysfunction (ED) is a common side-effect. PATIENTS AND METHODS: We identified 141 sexually active patients who underwent RP at Cleveland Clinic Foundation. Patients were offered various non-oral treatment options to prevent ED and were also motivated for early penile rehabilitation. At 5 years 62% remained sexually active, of whom 71% had natural erections sufficient for intercourse without assistance, 8.5% were still using sildenafil, 10% were using combined therapy (sildenafil plus VED). At 5 years 38% (43/113) men were sexually inactive. The reasons included loss of interest in 17 (40%), cardiovascular/neurological diseases in 18 (42%), hormonal therapy in three (7%), loss of partner in three (7%) and two had other surgery. The natural rate of erections for sufficient vaginal penetration without an erection aid were preserved and maintained in the early-prophylaxis group, and almost 60% of them had used a VED as early prophylaxis. CONCLUSION: Despite current phosphodiesterase-5 inhibitor treatments for ED, VED is becoming recognized again as having a primary role in early penile rehabilitation in many patients, specifically those treated for prostate cancer.
OBJECTIVE: To evaluate the long-term potency after radical prostatectomy (RP) with the early use of a vacuum erection device (VED), and reasons for sexual inactivity and long-term attrition and maintenance of sexual activity, as RP is one of the most common treatments for prostate cancer but erectile dysfunction (ED) is a common side-effect. PATIENTS AND METHODS: We identified 141 sexually active patients who underwent RP at Cleveland Clinic Foundation. Patients were offered various non-oral treatment options to prevent ED and were also motivated for early penile rehabilitation. At 5 years 62% remained sexually active, of whom 71% had natural erections sufficient for intercourse without assistance, 8.5% were still using sildenafil, 10% were using combined therapy (sildenafil plus VED). At 5 years 38% (43/113) men were sexually inactive. The reasons included loss of interest in 17 (40%), cardiovascular/neurological diseases in 18 (42%), hormonal therapy in three (7%), loss of partner in three (7%) and two had other surgery. The natural rate of erections for sufficient vaginal penetration without an erection aid were preserved and maintained in the early-prophylaxis group, and almost 60% of them had used a VED as early prophylaxis. CONCLUSION: Despite current phosphodiesterase-5 inhibitor treatments for ED, VED is becoming recognized again as having a primary role in early penile rehabilitation in many patients, specifically those treated for prostate cancer.
Authors: Tariq S Hakky; Adam S Baumgarten; Justin Parker; Yin Zheng; Mike Kongnyuy; Daniel Martinez; Rafael E Carrion Journal: Curr Urol Rep Date: 2014-04 Impact factor: 3.092
Authors: A Matthew; N Lutzky-Cohen; L Jamnicky; K Currie; A Gentile; D Santa Mina; N Fleshner; A Finelli; R Hamilton; G Kulkarni; M Jewett; A Zlotta; J Trachtenberg; Z Yang; D Elterman Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: G J Nason; F McNamara; M Twyford; F O'Kelly; S White; E Dunne; G C Durkan; S K Giri; G P Smyth; R E Power Journal: Int J Impot Res Date: 2016-05-26 Impact factor: 2.896
Authors: Alexander B Nolsøe; Christian Fuglesang S Jensen; Peter B Østergren; Mikkel Fode Journal: Int J Impot Res Date: 2020-12-14 Impact factor: 2.896